Rinvoq Description

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Warnings Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Full Prescribing Info

Description

RINVOQ 15 mg prolonged-release tablets: Purple 14 x 8 mm, oblong biconvex prolonged-release tablets imprinted on one side with 'a15'.
Each prolonged-release tablet contains upadacitinib hemihydrate, equivalent to 15 mg of upadacitinib.
RINVOQ 30 mg prolonged-release tablets: Red 14 x 8 mm, oblong biconvex prolonged-release tablets imprinted on one side with 'a30'.
Each prolonged-release tablet contains upadacitinib hemihydrate, equivalent to 30 mg of upadacitinib.
RINVOQ 45 mg prolonged-release tablets: Yellow to mottled yellow 14 x 8 mm, oblong biconvex prolonged-release tablets imprinted on one side with 'a45'.
Each prolonged-release tablet contains upadacitinib hemihydrate, equivalent to 45 mg of upadacitinib.
Excipients/Inactive Ingredients: Tablet contents: Microcrystalline cellulose, Hypromellose, Mannitol, Tartaric acid, Anhydrous colloidal silica, Magnesium stearate.
Film coating: Poly(vinyl alcohol), Macrogol, Talc, Titanium dioxide (E171), Iron oxide black (E172) (15 mg strength only), Iron oxide red (E172), Iron oxide yellow (E172) (45 mg strength only).

upadacitinib

Manufacturer:

AbbVie

Distributor:

DKSH